Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis.

IF 4.5 2区 医学 Q2 IMMUNOLOGY
A Stoltz, R R Nathavitharana, E de Kock, V Ueckermann, P Jensen, C M Mendel, M Spigelman, E A Nardell
{"title":"Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis.","authors":"A Stoltz, R R Nathavitharana, E de Kock, V Ueckermann, P Jensen, C M Mendel, M Spigelman, E A Nardell","doi":"10.1093/infdis/jiaf005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most drug-resistant tuberculosis occurs due to transmission of unsuspected or ineffectively treated drug-resistant tuberculosis. The duration of treatment to stop person-to-person spread of drug-resistant tuberculosis is uncertain. We evaluated the impact of novel regimens, including BPaL (bedaquiline, 1200-mg linezolid, and pretomanid), on drug-resistant tuberculosis transmission, using the human-guinea pig (H-GP) transmission model.</p><p><strong>Methods: </strong>In experiment 1, patients initiated an optimized drug-resistant tuberculosis regimen including bedaquiline and linezolid. In experiment 2, patients initiated the BPaL regimen. We measured baseline infectivity for each cohort by exhausting ward air to one of two guinea pig exposure rooms (control group), each containing 90 guinea pigs, for 8 patient-days. Then, after 72 hours of treatment, ward air was exhausted to the second guinea pig exposure room for 8 patient-days (intervention group). The infectiousness of each cohort was compared by performing tuberculin skin tests in guinea pigs at baseline (before treatment) and 6 weeks after the exposure period.</p><p><strong>Results: </strong>In experiment 1, before treatment, 5 patients with drug-resistant tuberculosis infected 24 of 90 guinea pigs (26.7%) (control group). After treatment (72 hours after drug initiation), the same patients infected 25 of 90 guinea pigs (27.8%) (intervention group) (P > .99). In experiment 2, before treatment, 9 patients with drug-resistant tuberculosis infected 40 of 90 guinea pigs (44.4%) (control group). After treatment (beginning 72 hours after drug initiation), the same patients infected 0 of 90 guinea pigs (0%) (intervention group) (P < .0001).</p><p><strong>Conclusions: </strong>In this study, drug-resistant tuberculosis drug regimens, including bedaquiline and standard-dose linezolid for 72 hours, did not decrease drug-resistant tuberculosis transmission. In contrast, transmission was rapidly and completely inhibited in patients treated with BPaL for 72 hours, suggesting an early and profound impact on transmission.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":"143-151"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308646/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Most drug-resistant tuberculosis occurs due to transmission of unsuspected or ineffectively treated drug-resistant tuberculosis. The duration of treatment to stop person-to-person spread of drug-resistant tuberculosis is uncertain. We evaluated the impact of novel regimens, including BPaL (bedaquiline, 1200-mg linezolid, and pretomanid), on drug-resistant tuberculosis transmission, using the human-guinea pig (H-GP) transmission model.

Methods: In experiment 1, patients initiated an optimized drug-resistant tuberculosis regimen including bedaquiline and linezolid. In experiment 2, patients initiated the BPaL regimen. We measured baseline infectivity for each cohort by exhausting ward air to one of two guinea pig exposure rooms (control group), each containing 90 guinea pigs, for 8 patient-days. Then, after 72 hours of treatment, ward air was exhausted to the second guinea pig exposure room for 8 patient-days (intervention group). The infectiousness of each cohort was compared by performing tuberculin skin tests in guinea pigs at baseline (before treatment) and 6 weeks after the exposure period.

Results: In experiment 1, before treatment, 5 patients with drug-resistant tuberculosis infected 24 of 90 guinea pigs (26.7%) (control group). After treatment (72 hours after drug initiation), the same patients infected 25 of 90 guinea pigs (27.8%) (intervention group) (P > .99). In experiment 2, before treatment, 9 patients with drug-resistant tuberculosis infected 40 of 90 guinea pigs (44.4%) (control group). After treatment (beginning 72 hours after drug initiation), the same patients infected 0 of 90 guinea pigs (0%) (intervention group) (P < .0001).

Conclusions: In this study, drug-resistant tuberculosis drug regimens, including bedaquiline and standard-dose linezolid for 72 hours, did not decrease drug-resistant tuberculosis transmission. In contrast, transmission was rapidly and completely inhibited in patients treated with BPaL for 72 hours, suggesting an early and profound impact on transmission.

估计耐药结核病新治疗方案的早期传播抑制作用。
导言:大多数耐药结核病(DR-TB)是由于未经怀疑或治疗无效的耐药结核病传播而发生的。阻止耐药结核病人际传播的治疗持续时间是不确定的。我们使用人-豚鼠(H-GP)传播模型评估了包括BPaL在内的新方案对耐药结核病传播的影响。方法:在实验1中,患者开始了优化的耐药结核病治疗方案,包括贝达喹啉(BDQ)和利奈唑胺(LZD)。在实验2中,患者开始BPaL方案(BDQ, 1200mg LZD和pretomanid)。我们通过将病房空气排到两个全科医生暴露室之一(对照组),每个房间有90个全科医生,持续8个病人日,来测量每个队列的基线传染性。治疗72小时后,将病房空气排至第二GP暴露室,持续8个病人天(干预)。通过在基线(治疗前)和暴露期后6周对全科医生进行结核菌素皮肤试验(TST),比较每个队列的传染性。结果:实验1治疗前,5例DR-TB患者感染了24/90(对照组)gp(26.7%)。治疗后(服药后72小时),相同患者感染25/90 (27.8%)gp(干预)(p = 1.00)。实验2治疗前,9例耐药结核病患者感染了40/90 (44.4%)gp(对照组)。治疗后(服药后72小时开始),相同的患者感染0/90 (0%)gp(干预)(p < 0.0001)。结论:在本研究中,包括BDQ和标准剂量LZD 72小时的耐药结核病药物方案并没有减少耐药结核病的传播。相比之下,BPaL治疗72小时后,传播迅速而完全被抑制,这表明BPaL对传播的早期和深远影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Infectious Diseases
Journal of Infectious Diseases 医学-传染病学
CiteScore
13.50
自引率
3.10%
发文量
449
审稿时长
2-4 weeks
期刊介绍: Published continuously since 1904, The Journal of Infectious Diseases (JID) is the premier global journal for original research on infectious diseases. The editors welcome Major Articles and Brief Reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. JID is an official publication of the Infectious Diseases Society of America.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信